HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a price target of $16.
May 22, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Esperion Therapeutics and maintained a price target of $16, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $16 price target by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Esperion Therapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100